Valuation: Edesa Biotech, Inc.

Market Cap 6.89Cr 6.05Cr 5.57Cr 5.19Cr 9.79Cr 655.17Cr 9.99Cr 67Cr 26Cr 321.6Cr 26Cr 25Cr 1.12TCr P/E 2026 *
-4.67x
P/E 2027 * -3.86x
Enterprise Value 6.89Cr 6.05Cr 5.57Cr 5.19Cr 9.79Cr 655.17Cr 9.99Cr 67Cr 26Cr 321.6Cr 26Cr 25Cr 1.12TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
79.78%
Yield 2026 *
-
Yield 2027 * -
1 day-4.67%
1 week-2.52%
Current month-4.67%
1 month+15.84%
3 months+39.64%
6 months+445.77%
Current year+445.77%
1 week 7.32
Extreme 7.32
8.89
1 month 4.56
Extreme 4.56
8.89
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
84
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 01/08/2015
Director of Finance/CFO 57 01/05/2025
President 48 07/06/2019
Director TitleAgeSince
Chairman 50 07/06/2019
Director/Board Member 55 07/06/2019
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap.
16/06Free

Founder

1,53,550 1.7268%
16/06Sell

Founder

1,53,530 1.7266%
01/06Free

Founder

1,671 0.0188%
Change 5-day change 1-year change 3-year change Capi.($)
-4.67%-2.52%+281.77%+36.53% 7.23Cr
-2.19%+6.01%+66.90%+123.30% 5.76TCr
+0.55%+8.49%+77.09%+100.93% 5.51TCr
+0.93%+4.11%-12.64%-12.98% 2.35TCr
+0.36%+3.42%+9.61%+407.11% 2.31TCr
+3.64%+8.34%+39.81%-5.88% 1.81TCr
+0.28%+5.51%+36.93%-30.23% 1.68TCr
+1.49%+17.24%+174.91%+344.55% 1.57TCr
-0.83%+2.06%+23.70%+182.37% 1.37TCr
+8.94%+14.98%+44.19% - 1.3TCr
Average +0.83%+5.95%+74.23%+127.30% 2.37TCr
Weighted average by Cap. +0.55%+6.56%+55.04%+129.80%

Financials

2026 *2027 *
Net sales - -
Net income -1.45Cr -1.28Cr -1.17Cr -1.09Cr -2.06Cr -138.2Cr -2.11Cr -14Cr -5.47Cr -68Cr -5.46Cr -5.34Cr -236.09Cr -2.65Cr -2.33Cr -2.14Cr -2Cr -3.77Cr -252.06Cr -3.84Cr -26Cr -9.98Cr -123.73Cr -9.95Cr -9.74Cr -430.6Cr
Net Debt - -
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
17
Date Price Change Volume
01/26/01 $7.750 -4.67% 46,468
30/26/30 $8.130 +6.00% 1,92,344
29/26/29 $7.670 -6.35% 75,183
26/26/26 $8.190 +9.64% 67,949
25/26/25 $7.470 -6.04% 1,30,275
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.750USD
Average target price
16.33USD
Spread / Average Target
+110.75%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EDSA Stock